Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Single-Payer Healthcare
  • Federal Workers’ Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

WHAT'S NEW

  • Single-Payer Healthcare
  • Federal Workers' Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Aug 15 2018

Full Issue

There's Been Few Breakthroughs In Alzheimer's Drugs In Decades. Where's The Demand For Progress?

In other diseases, loud and outraged patient advocates have played a crucial role in getting experimental treatments and drugs to trial. When it comes to Alzheimer's, though, experts say there isn't that energy to push for a cure. In other public health news: cancer and elephants, brain injuries, female doctors, race, Ebola and tainted blood pressure meds.

Stat: As Alzheimer's Drug Makers Abandon Today's Patients, Where Is The Outrage? 

When virologists and drug developers were too slow in finding ways to save the lives of people with HIV/AIDS and refused to give patients access to experimental drugs 30 years ago, activists chained themselves to a balcony on the New York Stock Exchange, held demonstrations where scores were arrested, and effectively shut down the Food and Drug Administration for a day. The lack of progress against Alzheimer’s disease has brought somewhat less outrage. Although the latest analysis of experimental Alzheimer’s drugs finds that literally zero are being tested in late-stage clinical trials to treat moderate to severe Alzheimer’s, no patient advocacy groups uttered a peep in protest. (Begley, 8/15)

The New York Times: The ‘Zombie Gene’ That May Protect Elephants From Cancer

Elephants ought to get a lot of cancer. They’re huge animals, weighing as much as eight tons. It takes a lot of cells to make up that much elephant. All of those cells arose from a single fertilized egg, and each time a cell divides, there’s a chance that it will gain a mutation — one that may lead to cancer. Strangely, however, elephants aren’t more prone to cancer than smaller animals. Some research even suggests they get less cancer than humans do. (Zimmer, 8/14)

The Washington Post: A Traumatic Brain Injury May Increase The Risk Of Suicide, Study Says

Traumatic brain injury is the leading cause of death and disability in young adults in the developed world. Suicide is the second leading cause of death for young people ages 15 to 24. Though the reasons for any particular suicide are often inscrutable, research published Tuesday in the Journal of the American Medical Association suggests that at least a fraction of the blame could be placed on traumatic brain injuries. (Nutt, 8/14)

The New York Times: Should You Choose A Female Doctor?

Does gender matter when choosing a doctor? Whether your doctor is male or female could be a matter of life or death, a new study suggests. The study, of more than 580,000 heart patients admitted over two decades to emergency rooms in Florida, found that mortality rates for both women and men were lower when the treating physician was female. And women who were treated by male doctors were the least likely to survive. (Parker-Pope, 8/14)

The New York Times: Black Boys Feel Less Safe In White Neighborhoods, Study Shows

Many black boys have been racially profiled, arrested or even killed in white neighborhoods because the residents were afraid of them. A new study suggests the boys are afraid, too. The study, which was released on Monday, found that “African-American boys experience a decreased sense of safety” when in neighborhoods with a larger white population than areas they normally frequent. Black boys “will expect increased scrutiny, surveillance and even direct targeting as they traverse whiter spaces,” the study found. Black girls did not report feeling significantly less safe in such areas. (Garcia, 8/14)

The Wall Street Journal: Ebola Outbreak Spreads To Conflict Zone In Democratic Republic Of Congo

A deadly outbreak of Ebola in the Democratic Republic of Congo has spread outside the province of North Kivu, the country’s health ministry said Tuesday, entering for the first time an active conflict zone and raising the threat of a wider outbreak. Forty-one people have died in Congo’s current epidemic, which started last month in the gold- and tin-mining heartlands of North Kivu. An earlier Ebola outbreak in Congo’s northwest had been declared over just a week earlier. (Bariyo, 8/14)

San Jose Mercury News: FDA Widens Its Recall Of Tainted Blood Pressure Drugs

Be aware that the FDA has widened its recall of tainted blood pressure medication containing the drug valsartan. A limited recall began in July but has since been expanded to this list of drugs. (D'Souza, 8/14)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 8
  • Thursday, May 7
  • Wednesday, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF